Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Akebia Therapeutics (Nasdaq: AKBA) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. CEO John Butler will deliver a presentation on Thursday, January 16, 2024, at 7:30 AM PST, which will include updates on the Vafseo® (vadadustat) U.S. launch and other business matters. The conference is scheduled for January 13-16, 2025, in San Francisco. Interested parties can access the presentation webcast through the 'Investors' section of Akebia's website after the conference.
Akebia Therapeutics (Nasdaq: AKBA) ha annunciato la sua partecipazione alla 43ª Conferenza Annuale J.P. Morgan Healthcare. Il CEO John Butler presenterà giovedì 16 gennaio 2024, alle 7:30 AM PST, un aggiornamento sul lancio negli Stati Uniti di Vafseo® (vadadustat) e altre questioni aziendali. La conferenza si svolgerà dal 13 al 16 gennaio 2025 a San Francisco. Le parti interessate possono accedere alla registrazione della presentazione tramite la sezione 'Investitori' del sito web di Akebia dopo la conferenza.
Akebia Therapeutics (Nasdaq: AKBA) ha anunciado su participación en la 43ª Conferencia Anual J.P. Morgan Healthcare. El CEO John Butler realizará una presentación el jueves 16 de enero de 2024, a las 7:30 AM PST, que incluirá actualizaciones sobre el lanzamiento en EE.UU. de Vafseo® (vadadustat) y otros asuntos comerciales. La conferencia está programada del 13 al 16 de enero de 2025 en San Francisco. Las partes interesadas pueden acceder a la transmisión de la presentación a través de la sección 'Inversores' en el sitio web de Akebia después de la conferencia.
아케비아 테라퓨틱스 (Nasdaq: AKBA)는 제43회 연례 JP모건 헬스케어 회의에 참가한다고 발표했습니다. CEO 존 버틀러는 2024년 1월 16일 목요일 오전 7시 30분 PST에 Vafseo® (바다두스타트) 미국 출시 및 기타 사업사항에 대한 업데이트를 포함한 발표를 진행할 예정입니다. 회의는 2025년 1월 13일부터 16일까지 샌프란시스코에서 열릴 예정입니다. 관심 있는 분들은 회의 후 아케비아 웹사이트의 '투자자' 섹션을 통해 발표 웹캐스트에 접근할 수 있습니다.
Akebia Therapeutics (Nasdaq: AKBA) a annoncé sa participation à la 43e Conférence Annuelle J.P. Morgan Healthcare. Le PDG John Butler fera une présentation le jeudi 16 janvier 2024, à 7h30 PST, qui inclura des mises à jour sur le lancement de Vafseo® (vadadustat) aux États-Unis et d'autres affaires. La conférence est prévue du 13 au 16 janvier 2025 à San Francisco. Les parties intéressées peuvent accéder à la diffusion de la présentation via la section 'Investisseurs' du site Web d'Akebia après la conférence.
Akebia Therapeutics (Nasdaq: AKBA) hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare-Konferenz angekündigt. CEO John Butler wird am Donnerstag, den 16. Januar 2024, um 7:30 Uhr PST eine Präsentation halten, die Updates zum Markteinführung von Vafseo® (Vadadustat) in den USA und anderen Geschäftsthemen enthalten wird. Die Konferenz ist für den 13. bis 16. Januar 2025 in San Francisco geplant. Interessierte Parteien können nach der Konferenz über den Bereich 'Investoren' auf der Website von Akebia auf das Webcast der Präsentation zugreifen.
- None.
- None.
A webcast of the presentation can be accessed through the "Investors" section of Akebia's website at https://ir.akebia.com following the conference.
The J.P. Morgan Healthcare Conference will take place January 13-16, 2025 in
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference-302334295.html
SOURCE Akebia Therapeutics, Inc.
FAQ
When will Akebia Therapeutics (AKBA) present at the 2024 J.P. Morgan Healthcare Conference?
What topics will be covered in AKBA's presentation at the J.P. Morgan Healthcare Conference?
How can investors access AKBA's J.P. Morgan Healthcare Conference presentation?
What is the focus of Akebia Therapeutics' (AKBA) business?
